Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma

被引:119
作者
Lee, Xiaolong [1 ]
Gao, Ming [1 ]
Ji, Yifeng [1 ]
Yu, Yang [1 ]
Feng, Ying [1 ]
Li, Yigong [1 ]
Zhang, Yan [1 ]
Cheng, Wenyuan [1 ]
Zhao, Wenchuan [1 ]
机构
[1] Tianjin Med Univ, Canc Hosp, Dept Thyroid & Neck, Tianjin, Peoples R China
关键词
LYMPH-NODE METASTASIS; BRAF MUTATIONS; HIGH PREVALENCE; PROGNOSTIC-FACTORS; CARCINOMA; CANCERS; DIAGNOSIS; DEDIFFERENTIATION; RECURRENCE; EXPRESSION;
D O I
10.1245/s10434-008-0233-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF(V600E) mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAF(V600E) mutational status of them was identified. BRAF(V600E) mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAF(V600E) mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAF(V600E) mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF(V600E) mutation may be a marker of high aggressiveness in PTMCs.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 34 条
[1]   Papillary microcarcinoma of the thyroid - Prognostic significance of lymph node metastasis and multifocality [J].
Chow, SM ;
Law, SCK ;
Chan, JKC ;
Au, SK ;
Yau, S ;
Lau, WH .
CANCER, 2003, 98 (01) :31-40
[2]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[3]   BRAF mutations in an Italian cohort of thyroid cancers [J].
Fugazzola, L ;
Mannavola, D ;
Cirello, V ;
Vannucchi, G ;
Muzza, M ;
Vicentini, L ;
Beck-Peccoz, P .
CLINICAL ENDOCRINOLOGY, 2004, 61 (02) :239-243
[4]   BRAF mutations in papillary carcinomas of the thyroid [J].
Fukushima, T ;
Suzuki, S ;
Mashiko, M ;
Ohtake, T ;
Endo, Y ;
Takebayashi, Y ;
Sekikawa, K ;
Hagiwara, K ;
Takenoshita, S .
ONCOGENE, 2003, 22 (41) :6455-6457
[5]  
HAY ID, 1992, SURGERY, V112, P1139
[6]   Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications [J].
Jukkola, A ;
Bloigu, R ;
Ebeling, T ;
Salmela, P ;
Blanco, G .
ENDOCRINE-RELATED CANCER, 2004, 11 (03) :571-579
[7]   Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population [J].
Kim, KH ;
Kang, DW ;
Kim, SH ;
Seong, IO ;
Kang, DY .
YONSEI MEDICAL JOURNAL, 2004, 45 (05) :818-821
[8]  
Kimura ET, 2003, CANCER RES, V63, P1454
[9]   Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation [J].
Knauf, JA ;
Ma, XL ;
Smith, EP ;
Zhang, L ;
Mitsutake, N ;
Liao, XH ;
Refetoff, S ;
Nikiforov, YE ;
Fagin, JA .
CANCER RESEARCH, 2005, 65 (10) :4238-4245
[10]   Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis [J].
Leboulleux, S ;
Rubino, C ;
Baudin, E ;
Caillou, B ;
Hartl, DM ;
Bidart, JM ;
Travagli, JP ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5723-5729